Trial record 2 of 5 for:
svn53
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03879694 |
|
Recruitment Status :
Recruiting
First Posted : March 19, 2019
Last Update Posted : January 6, 2021
|
Sponsor:
Roswell Park Cancer Institute
Collaborators:
NeuroEndocrine Tumor Research Foundation (NETRF)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 31, 2021 |
| Estimated Study Completion Date : | January 31, 2022 |